Loading
Every dated change on the records linked to Ovarian cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Platinum-resistant PD-L1+ ovarian cancer; adjuvant RCC with belzutifan; with sacituzumab govitecan in 1L TNBC
Platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer with nab-paclitaxel
A milestone in how this cancer is treated.
First immunotherapy approval in ovarian cancer (February 2026).
KRAS-mutated recurrent low-grade serous ovarian cancer after prior systemic therapy (accelerated)
OS 18.
ORR 55.
OS 16.
A milestone in how this cancer is treated.
PFS HR 0.
OS 16.
First-line maintenance benefit confirmed while later-line PARP use retreats after OS imbalances (ARIEL4, SOLO3).
FRα-high platinum-resistant ovarian cancer (full approval 2024)
PFS 20.
Objective responses in about a third of patients with folate receptor alpha-high platinum-resistant ovarian cancer; accelerated approval in November 2022.
Accelerated approval; full approval after MIRASOL OS benefit in 2024.
A milestone in how this cancer is treated.
Intraoperative imaging of ovarian cancer lesions in adults
No significant reduction in ovarian cancer mortality.
A milestone in how this cancer is treated.
First-line maintenance with olaparib in HRD-positive ovarian cancer
Companion diagnostic for olaparib plus bevacizumab first-line maintenance in HRD-positive ovarian cancer
First-line advanced ovarian, fallopian-tube or primary-peritoneal maintenance after platinum response; current scope is HRD-positive with FDA-authorised companion diagnostic
First-line ovarian maintenance with bevacizumab for HRD-positive disease
OS 53.
Companion diagnostic for niraparib in HRD-positive advanced ovarian cancer
PFS HR 0.
PFS HR 0.
PRIMA (niraparib, all comers) and PAOLA-1 (olaparib + bevacizumab, HRD-positive).
First-line stage III-IV ovarian cancer after surgery
Germline or somatic BRCA-mutated advanced ovarian first-line maintenance after platinum response
Recurrent ovarian, fallopian-tube or primary-peritoneal maintenance after platinum response; current scope is germline or somatic BRCA-mutated
OS 45.
PFS HR 0.
Two years of first-line olaparib maintenance (PFS HR 0.30) and HIPEC at interval surgery (OS +12 months) both reported.
Recurrent ovarian, fallopian-tube or primary-peritoneal maintenance after platinum response; current scope is germline BRCA-mutated
Recurrent ovarian maintenance after platinum response; current scope is germline or somatic BRCA-mutated
Platinum-resistant ovarian cancer with chemotherapy; recurrent/metastatic cervical cancer with chemotherapy
Companion diagnostic for olaparib in germline BRCA-mutated advanced ovarian cancer
Historical germline-BRCA advanced ovarian cancer after at least three chemotherapy lines; treatment indication withdrawn
Median progression-free survival 6.
A milestone in how this cancer is treated.
For germline BRCA-mutated ovarian cancer after three lines.